title: Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).
abstract: The ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy. This complication is unusual as it is not the consequence of a treatment which is vital or mandatory for the patient's health. Nevertheless, it can be accompanied by severe morbidity and may even be fatal. Data pertaining to the clinical course and consequences of OHSS in women and its treatment were searched using Medline, Current Contents and PubMed. To date, only a few studies have collected a large number of cases of OHSS. The clinical course of OHSS may involve, according to its severity and the occurrence of pregnancy, electrolytic imbalance, neurohormonal and haemodynamic changes, pulmonary manifestations, liver dysfunction, hypoglobulinaemia, febrile morbidity, thromboembolic phenomena, neurological manifestations and adnexal torsion. Treatment of the acute phase relies only on an empirical and symptomatic approach. The general approach will be adapted to the levels of severity. Specific approaches such as paracentesis, pleural puncture, surgical approach of OHSS and specific medication during OHSS were evaluated sporadically. More adequate treatment methods would require a better understanding of the underlying pathophysiological mechanisms, to promote an aetiological therapeutic approach. Properly conducted studies, including large numbers of patients are required in order to determine the best method of prevention and management.
authors.affiliation: IVF Centre, Department of Obstetrics-Gynaecology, University Hospital St Pierre (Free University of Brussels ULB), Brussels, Belgium. annick.delvigne@swing.be
authors.forename: Annick
authors.initials: A
authors.lastname: Delvigne
authors.forename: Serge
authors.initials: S
authors.lastname: Rozenberg
mesh_terms: D005260:Female; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000628:therapy*; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy